Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy

Yoshiyasu Aizawa, Yoko Tanimoto, Yoshiko Hirata, Taishi Fujisawa, Ryoma Fukuoka, Kazuaki Nakajima, Yoshinori Katsumata, Takahiko Nishiyama, Takehiro Kimura, Shinsuke Yuasa, Takashi Kohno, Shun Kohsaka, Mitsushige Murata, Yuichiro Maekawa, Yoshiko Furukawa, Seiji Takatsuki, Keiichi Fukuda

Research output: Contribution to journalArticle

Abstract

Some patients with hypertrophic cardiomyopathy (HCM) develop systolic dysfunction, called the dilated phase of HCM (d-HCM), which is associated with increased morbidity and mortality. We conducted a retrospective study using an HCM database to clarify the incidence, clinical characteristics, and long-term outcomes of d-HCM. We analyzed an HCM cohort consisting of 434 patients (273 with apical HCM and 161 with non-apical HCM; 18 had obstructive HCM, 16 had dilated HCM, and 127 had other HCM) diagnosed by echocardiography in our hospital between 1991 and 2010. The follow-up period was 8.4 ± 6.7 years. The mean age at final follow-up was 67 ± 14 years, and 304 patients (70%) were men. The mean age of the 16 d-HCM patients at the initial visit was 45 ± 17 years, the age at final follow-up was 59 ± 18 years, and 13 were men. Thirteen d-HCM patients developed atrial fibrillation and six patients developed ischemic stroke. Twelve d-HCM patients were implanted with cardiac devices: one pacemaker, nine implantable cardioverter-defibrillators, and two cardiac resynchronization therapy with defibrillator. Five patients died of progressive heart failure at the age of 61 ± 23 years. The age at the initial visit and final follow-up were lower and the NYHA class, brain natriuretic peptide levels, and left ventricular function at initial evaluation were worse in the d-HCM group. Univariate analysis demonstrated that a lower age at the initial visit was associated with d-HCM (hazard ratio 0.955/1 year increase; 95% CI 0.920–0.991, P = 0.015). In our HCM cohort, the incidence of d-HCM was 4%. A high prevalence of atrial fibrillation and cerebral infarction and poor prognosis were noted in this group, despite patients undergoing medication and device implantation.

Original languageEnglish
Pages (from-to)87-94
Number of pages8
JournalKeio Journal of Medicine
Volume68
Issue number4
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Hypertrophic Cardiomyopathy
Incidence
Atrial Fibrillation
Equipment and Supplies
Cardiac Resynchronization Therapy
Defibrillators
Implantable Defibrillators
Brain Natriuretic Peptide
Cerebral Infarction
Dilated Cardiomyopathy
Left Ventricular Function
Echocardiography
Heart Failure
Retrospective Studies
Stroke
Databases
Morbidity
Mortality

Keywords

  • Dilated phase
  • Hypertrophic cardiomyopathy
  • Prognosis
  • Systolic dysfunction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy. / Aizawa, Yoshiyasu; Tanimoto, Yoko; Hirata, Yoshiko; Fujisawa, Taishi; Fukuoka, Ryoma; Nakajima, Kazuaki; Katsumata, Yoshinori; Nishiyama, Takahiko; Kimura, Takehiro; Yuasa, Shinsuke; Kohno, Takashi; Kohsaka, Shun; Murata, Mitsushige; Maekawa, Yuichiro; Furukawa, Yoshiko; Takatsuki, Seiji; Fukuda, Keiichi.

In: Keio Journal of Medicine, Vol. 68, No. 4, 01.01.2019, p. 87-94.

Research output: Contribution to journalArticle

Aizawa, Y, Tanimoto, Y, Hirata, Y, Fujisawa, T, Fukuoka, R, Nakajima, K, Katsumata, Y, Nishiyama, T, Kimura, T, Yuasa, S, Kohno, T, Kohsaka, S, Murata, M, Maekawa, Y, Furukawa, Y, Takatsuki, S & Fukuda, K 2019, 'Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy', Keio Journal of Medicine, vol. 68, no. 4, pp. 87-94. https://doi.org/10.2302/kjm.2018-0004-OA
Aizawa, Yoshiyasu ; Tanimoto, Yoko ; Hirata, Yoshiko ; Fujisawa, Taishi ; Fukuoka, Ryoma ; Nakajima, Kazuaki ; Katsumata, Yoshinori ; Nishiyama, Takahiko ; Kimura, Takehiro ; Yuasa, Shinsuke ; Kohno, Takashi ; Kohsaka, Shun ; Murata, Mitsushige ; Maekawa, Yuichiro ; Furukawa, Yoshiko ; Takatsuki, Seiji ; Fukuda, Keiichi. / Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy. In: Keio Journal of Medicine. 2019 ; Vol. 68, No. 4. pp. 87-94.
@article{9cd65cb3ffec4a5d8cb0201ddb1e2990,
title = "Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy",
abstract = "Some patients with hypertrophic cardiomyopathy (HCM) develop systolic dysfunction, called the dilated phase of HCM (d-HCM), which is associated with increased morbidity and mortality. We conducted a retrospective study using an HCM database to clarify the incidence, clinical characteristics, and long-term outcomes of d-HCM. We analyzed an HCM cohort consisting of 434 patients (273 with apical HCM and 161 with non-apical HCM; 18 had obstructive HCM, 16 had dilated HCM, and 127 had other HCM) diagnosed by echocardiography in our hospital between 1991 and 2010. The follow-up period was 8.4 ± 6.7 years. The mean age at final follow-up was 67 ± 14 years, and 304 patients (70{\%}) were men. The mean age of the 16 d-HCM patients at the initial visit was 45 ± 17 years, the age at final follow-up was 59 ± 18 years, and 13 were men. Thirteen d-HCM patients developed atrial fibrillation and six patients developed ischemic stroke. Twelve d-HCM patients were implanted with cardiac devices: one pacemaker, nine implantable cardioverter-defibrillators, and two cardiac resynchronization therapy with defibrillator. Five patients died of progressive heart failure at the age of 61 ± 23 years. The age at the initial visit and final follow-up were lower and the NYHA class, brain natriuretic peptide levels, and left ventricular function at initial evaluation were worse in the d-HCM group. Univariate analysis demonstrated that a lower age at the initial visit was associated with d-HCM (hazard ratio 0.955/1 year increase; 95{\%} CI 0.920–0.991, P = 0.015). In our HCM cohort, the incidence of d-HCM was 4{\%}. A high prevalence of atrial fibrillation and cerebral infarction and poor prognosis were noted in this group, despite patients undergoing medication and device implantation.",
keywords = "Dilated phase, Hypertrophic cardiomyopathy, Prognosis, Systolic dysfunction",
author = "Yoshiyasu Aizawa and Yoko Tanimoto and Yoshiko Hirata and Taishi Fujisawa and Ryoma Fukuoka and Kazuaki Nakajima and Yoshinori Katsumata and Takahiko Nishiyama and Takehiro Kimura and Shinsuke Yuasa and Takashi Kohno and Shun Kohsaka and Mitsushige Murata and Yuichiro Maekawa and Yoshiko Furukawa and Seiji Takatsuki and Keiichi Fukuda",
year = "2019",
month = "1",
day = "1",
doi = "10.2302/kjm.2018-0004-OA",
language = "English",
volume = "68",
pages = "87--94",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "4",

}

TY - JOUR

T1 - Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy

AU - Aizawa, Yoshiyasu

AU - Tanimoto, Yoko

AU - Hirata, Yoshiko

AU - Fujisawa, Taishi

AU - Fukuoka, Ryoma

AU - Nakajima, Kazuaki

AU - Katsumata, Yoshinori

AU - Nishiyama, Takahiko

AU - Kimura, Takehiro

AU - Yuasa, Shinsuke

AU - Kohno, Takashi

AU - Kohsaka, Shun

AU - Murata, Mitsushige

AU - Maekawa, Yuichiro

AU - Furukawa, Yoshiko

AU - Takatsuki, Seiji

AU - Fukuda, Keiichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Some patients with hypertrophic cardiomyopathy (HCM) develop systolic dysfunction, called the dilated phase of HCM (d-HCM), which is associated with increased morbidity and mortality. We conducted a retrospective study using an HCM database to clarify the incidence, clinical characteristics, and long-term outcomes of d-HCM. We analyzed an HCM cohort consisting of 434 patients (273 with apical HCM and 161 with non-apical HCM; 18 had obstructive HCM, 16 had dilated HCM, and 127 had other HCM) diagnosed by echocardiography in our hospital between 1991 and 2010. The follow-up period was 8.4 ± 6.7 years. The mean age at final follow-up was 67 ± 14 years, and 304 patients (70%) were men. The mean age of the 16 d-HCM patients at the initial visit was 45 ± 17 years, the age at final follow-up was 59 ± 18 years, and 13 were men. Thirteen d-HCM patients developed atrial fibrillation and six patients developed ischemic stroke. Twelve d-HCM patients were implanted with cardiac devices: one pacemaker, nine implantable cardioverter-defibrillators, and two cardiac resynchronization therapy with defibrillator. Five patients died of progressive heart failure at the age of 61 ± 23 years. The age at the initial visit and final follow-up were lower and the NYHA class, brain natriuretic peptide levels, and left ventricular function at initial evaluation were worse in the d-HCM group. Univariate analysis demonstrated that a lower age at the initial visit was associated with d-HCM (hazard ratio 0.955/1 year increase; 95% CI 0.920–0.991, P = 0.015). In our HCM cohort, the incidence of d-HCM was 4%. A high prevalence of atrial fibrillation and cerebral infarction and poor prognosis were noted in this group, despite patients undergoing medication and device implantation.

AB - Some patients with hypertrophic cardiomyopathy (HCM) develop systolic dysfunction, called the dilated phase of HCM (d-HCM), which is associated with increased morbidity and mortality. We conducted a retrospective study using an HCM database to clarify the incidence, clinical characteristics, and long-term outcomes of d-HCM. We analyzed an HCM cohort consisting of 434 patients (273 with apical HCM and 161 with non-apical HCM; 18 had obstructive HCM, 16 had dilated HCM, and 127 had other HCM) diagnosed by echocardiography in our hospital between 1991 and 2010. The follow-up period was 8.4 ± 6.7 years. The mean age at final follow-up was 67 ± 14 years, and 304 patients (70%) were men. The mean age of the 16 d-HCM patients at the initial visit was 45 ± 17 years, the age at final follow-up was 59 ± 18 years, and 13 were men. Thirteen d-HCM patients developed atrial fibrillation and six patients developed ischemic stroke. Twelve d-HCM patients were implanted with cardiac devices: one pacemaker, nine implantable cardioverter-defibrillators, and two cardiac resynchronization therapy with defibrillator. Five patients died of progressive heart failure at the age of 61 ± 23 years. The age at the initial visit and final follow-up were lower and the NYHA class, brain natriuretic peptide levels, and left ventricular function at initial evaluation were worse in the d-HCM group. Univariate analysis demonstrated that a lower age at the initial visit was associated with d-HCM (hazard ratio 0.955/1 year increase; 95% CI 0.920–0.991, P = 0.015). In our HCM cohort, the incidence of d-HCM was 4%. A high prevalence of atrial fibrillation and cerebral infarction and poor prognosis were noted in this group, despite patients undergoing medication and device implantation.

KW - Dilated phase

KW - Hypertrophic cardiomyopathy

KW - Prognosis

KW - Systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85072121198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072121198&partnerID=8YFLogxK

U2 - 10.2302/kjm.2018-0004-OA

DO - 10.2302/kjm.2018-0004-OA

M3 - Article

C2 - 30606897

AN - SCOPUS:85072121198

VL - 68

SP - 87

EP - 94

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 4

ER -